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Research in Context 
Evidence Before the Study 
We searched for articles in PubMed prior to September 2018, without date limitations, 
for outcomes of children with “B-cell precursor (BCP) acute lymphoblastic leukaemia” 
and “bone marrow relapse”; further refined to include only those with a relapse 36 
months after first diagnosis or more than 6 months after stopping frontline therapy and 
who were treated uniformly for relapse with MRD measured post induction. Two 
relevant contemporary studies were identified. The Children’s Oncology Group ALL 
01P2 study treated 55 BCP acute lymphoblastic leukaemia patients with late bone 
marrow relapses (LBMR). 1-year EFS for those with end induction (EOI) MRD of <10-
4 and MRD ≥10-4 were 86% ± 8% and 77% ± 9%, p = 0·005 respectively. Details of 
allogeneic stem cell transplant (SCT) were not available. The BFM REZ 2002 study 
treated 236 patients with BCP acute lymphoblastic leukaemia and LBMR. The 8-year 
EFS of those with EOI MRD <10-3 stratified for no SCT, and in those with EOI MRD ≥ 
10-3 stratified for SCT, were 70% ± 5%, and 64% ± 5%, p = 0·29 respectively. We next 
searched for articles for outcomes of children with relapsed BCP acute lymphoblastic 
leukaemia with MRD assessment prior to SCT. Six articles were identified. Five were 
retrospective, not stratified by the time to relapse and identified a pre-SCT MRD of 
≥10-4 as predictive of relapse post SCT. The BFM REZ 96 and 2002 trial prospectively 
analysed pre-SCT MRD in 35 BCP acute lymphoblastic leukaemia with LBMR. The 4-
year EFS in patients with pre-SCT MRD <10-4 and ≥10-4 were 68% ± 12% and 20% ± 
12%, p = 0·02 respectively. These studies suggest a proportion of children with BCP 
acute lymphoblastic leukaemia and LBMR do not require SCT to maintain long term 
remission as determined by EOI MRD. For those requiring a transplant, a pre-SCT 
MRD ≥10-4 is associated with a high recurrence rates post SCT. 
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Added Value Of This Study   
In this prospectively analysed cohort of BCP acute lymphoblastic leukaemia with 
LBMR, an EOI MRD of ≥10-4 was used to stratify patients to SCT. Patients with MRD 
<10-4 had significantly better PFS and OS compared to those with higher MRD levels, 
suggesting this as the preferred MRD level to select patients for SCT or no-SCT. 
Higher MRD levels and poor outcomes were associated with high risk cytogenetic 
groups and those with IKZF1/PAX5/NR3C1 deletions or NRAS mutations. Patients 
with pre-SCT MRD levels ≥10-4, had reasonable outcomes after SCT.  
 
Implications Of All Available Evidence 
An EOI MRD <10-4 in BCP acute lymphoblastic leukaemia with LBMR is associated 
with favourable outcomes with systemic chemotherapy and avoiding cranial irradiation 
in those without CNS involvement. In this group, improvements in sensitivity of MRD 
technologies may allow further refinement in the future; second relapses are 
salvageable with a SCT in CR3, and experimental therapies will require careful 
evaluation. While patients with EOI MRD ≥10-4 benefit from SCT, transplant related 
mortality and relapse post SCT remain problematical and this group may show benefit 
with newer treatment modalities.   
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Abstract 
Background 
The outcomes of children with late bone marrow relapses (LBMR) in B-cell precursor 
(BCP) acute lymphoblastic leukaemia treated on the ALLR3 clinical trial were 
analysed.  
Methods 
Children aged 1-18 years, with BCP acute lymphoblastic leukaemia LBMR recruited 
to the randomised ALLR3 clinical trial were eligible for the study. The study opened to 
recruitment on January 31st, 2003, randomisation closed on December 31st 2007 and 
the trial closed on October 31st 2013. Treatment allocation was based on end of 
induction (EOI) minimal residual disease (MRD) measured by Ig/TR. Patients with EOI 
MRD ≥10-4, were allocated to allogeneic stem cell transplant (SCT) and those with 
MRD <10-4 to receive chemotherapy. The primary endpoint of the original ALLR3 
clinical trial was progression free survival (PFS) of randomised patients. The primary 
endpoint of the long term follow up cohort post closure of the randomisation was PFS 
of the MRD stratified LBMR patients.  Outcomes were correlated with age, site, time 
to recurrence, genetic subtypes and analysed by both intention to treat and treatment 
received. The trial was registered on the international trial registry 
https://doi.org/10.1186/ISRCTN45724312  and national clinical trials registry 
https://clinicaltrials.gov/ct2/show/NCT00967057.  
Findings 
The PFS of LBMR BCP acute lymphoblastic leukaemia on the ALL R3 trial was 60% 
(95% CI 54-70). 110 LBMR patients with EOI MRD ≥10-4 were allocated to SCT and 
82 with EOI MRD <10-4 to chemotherapy. In those allocated to SCT, there were 4 
relapses and 3 deaths prior to reaching SCT and 11 patients were not transplanted. 
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Of the 92 patients transplanted, 58 (63%) are in CR2, 13 died of complications and 23 
relapsed post-SCT. In those allocated for chemotherapy, there was 1 early treatment 
related death and 11 patients were transplanted. Of the 70 who continued on 
chemotherapy, 49 (70%) are in CR2, 2 died of complications and 19 have relapsed. 
The PFS of patients with MRD <10-4 and MRD ≥10-4 were 72% (95% CI 60-81) and 
56% (46-65) (p = 0·0078) respectively.  The long-term follow-up evaluated outcomes 
and not any other serious adverse events.  
Interpretation 
BCP acute lymphoblastic leukaemia with LBMR and EOI MRD<10-4 treated on ALLR3 
had favourable outcomes without a SCT. Patients with MRD≥10-4 benefited from SCT  
and in the future targeted therapies may offer further improvements in outcomes for 
these patients.  
Funding 
Bloodwise (Formerly Leukaemia and Lymphoma Research) UK, Cancer Research 
UK, Sporting Chance Cancer Foundation and National Health and Medical Research 
Council Australia, KindreneKankervrij Netherlands, European Union Seventh 
Framework Programme, India Alliance Wellcome DBT Margdarshi Fellowship (VS).  
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Introduction  
Outcomes after isolated or combined bone marrow relapses in childhood B-cell 
precursor (BCP) acute lymphoblastic leukaemia are related to the duration of first 
remission (CR1). Irrespective of treatment strategies, children relapsing more than 6 
months after stopping therapy have better survival rates (45-73% overall survival), 1-4 
suggesting that recurring blasts remain chemosensitive in many patients. The BFM 
group showed that low levels of minimal residual disease (MRD <10-3) at end of 
induction (EOI) identified a subset of patients with late bone marrow relapses (isolated 
or combined) (LBMR) who could be maintained in second remission (CR2) with 
chemotherapy and targeted radiotherapy. 5 Those with MRD ≥10-3 on the other hand, 
frequently experienced a second relapse. The Children’s Oncology Group (USA), in a 
smaller cohort of patients, demonstrated significantly better outcomes in patients with 
EOI MRD <104. 6 Consequently, the ALLREZ BFM 2002 clinical trial used a strategy 
of assigning patients with EOI MRD ≥10-3 to allogeneic stem cell transplantation 
(SCT). Those with EOI MRD <10-3 were allocated to chemotherapy with cranial 
irradiation for isolated LBMR and targeted radiotherapy for combined relapses. 3 The 
international collaborative ALLR3 clinical trial recommended SCT for patients with 
BCP-ALL and LBMR with an EOI MRD of ≥10-4, as it used a 4-drug anthracycline-
based induction, similar to the COG trial and in contrast to the ALLREZ BFM protocol. 
Chemotherapy had a significant impact in the ALLR3 trial in which a randomisation of 
idarubicin versus mitoxantrone in induction showing a significant benefit of 
mitoxantrone over idarubicin, despite comparable EOI MRD levels in the two arms. 7 
This paper did not report on the outcomes of the MRD risk stratification. 
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Other biological factors and treatment impact on the outcomes for relapsed acute 
lymphoblastic leukaemia, also independent of the MRD response. In particular, high-
risk cytogenetics and deletions/mutations in TP53 were shown to be associated with 
poor outcomes in LBMR patients, irrespective of the EOI MRD status. 8,9 Here, we 
report the long term follow up of late isolated and combined bone marrow relapses in 
BCP ALL patients treated on the ALLR3 protocol, stratified for chemotherapy only or 
SCT based on EOI MRD. We further investigate the influence of cytogenetics, 
previously identified prognostic somatic copy number alterations (SCNA) 8 and 
recurrent gene mutations, including the recent characterisation of IKZFplus. 10    
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Methods 
Study Design and Participants 
Children aged 1-18 years with isolated or combined LBMR of BCP acute lymphoblastic 
leukaemia and treated on the ALL R3 protocol (UK, Ireland, The Netherlands, 
Australia, New Zealand) 9 were included in the analyses.  The study recruited from 
31st January 2003 and closed to recruitment on 31st October 2013. The study was 
approved by the relevant ethics committees and patients were recruited after written 
consent. The outcome of late isolated extramedullary relapses have been previously 
published and excluded from these analyses. 11 This trial was registered on the 
international trial registry https://doi.org/10.1186/ISRCTN45724312  and national 
clinical trials registry https://clinicaltrials.gov/ct2/show/NCT00967057.  
 
Risk stratification and results of the randomised study along with the detailed ALLR3 
protocol have been reported previously 7,8,11 and are presented in brief in supplemental 
table S1 (webappendix page 1). From 31st January 2003 till 31st December 2007, 
patients were randomised to receive either mitoxantrone or idarubicin in induction. 
Following termination of the randomisation, patients continued on mitoxantrone until 
closure of the trial on 31st October 2013. Late relapses were defined as occurring 
more than 6 months after the end of front-line therapy. Isolated LBMR was defined as 
> 25% blasts in the bone marrow and combined LBMR as >5% bone marrow blasts, 
along with at least one extramedullary disease site. CNS relapse was defined as 
pleocytosis (> 5 blasts/µL) with blasts in the cerebrospinal fluid (CSF). Testicular 
disease was diagnosed clinically and confirmed by biopsy or ultrasonography. All 
LBMR patients were treated with 3 blocks of chemotherapy. Patients achieved second 
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complete remission (CR2) when bone marrow blasts were < 5% at the end of induction 
(with normal CSF findings if concomitant CNS disease).  
 
Procedures 
Minimal residual disease (MRD) was measured from marrow samples obtained at the 
end of induction (timepoint TP1) and prior to SCT/ end of block III chemotherapy (TP2) 
using real time quantitative polymerase chain reaction (qPCR) analysis of 
immunoglobulin and T-cell receptor gene rearrangements. 7,12 TP1 MRD (≥10-4) 
measured by at least one marker was reported as MRDhigh and MRD<10-4 determined 
by two sensitive markers as MRDlow. All others, including where MRD was not done 
or markers had lower sensitivity, were reported as not available (NA). Patients with 
isolated or combined LBMR and MRDhigh levels after induction were eligible for 
matched donor (MD) SCT following completion of the third (or Phase III) treatment 
block. Those with MRD levels <10-4 (MRDlow) continued with further chemotherapy 
alone (isolated LBMR) or with site-directed radiotherapy (combined LBMR). Where 
MRD was uninformative, those with a relapse less than 24 months from stopping 
therapy were eligible for SCT. 1,7  In this paper, stem cell donors matched at 10/10 
HLA loci were classified as MD and the rest as mismatched donors (MMD), including 
mismatched unrelated and haploidentical related donors. ‘Cord’ refers to SCT 
performed using donor cord blood stem cells.  
 
Cytogenetic analysis was done locally and reviewed centrally by the Leukaemia 
Research Cytogenetics Group. Where cytogenetics was not available for relapse, 
cytogenetics at first presentation was used. Integrated cyto- and molecular genetics, 
were used to categorise patients as standard, intermediate and high-risk genetic 
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groups as reported previously.7  The copy number status of IKZF1, CDKN2A/B, PAX5, 
EBF1, ETV6, BTG1, RB1, NR3C1 and PAR1 were determined using the SALSA 
Multiplex Ligation dependent Probe Amplification (MLPA) kit P335 (MRC Holland, The 
Netherlands). TP53 deletions were assessed by a combination of cytogenetics and 
MLPA using the P056 kit.  Key exons of TP53, NRAS, KRAS, PTPN11, FLT3, and 
CBL genes were assessed for mutations by denaturing high-performance liquid 
chromatography and Sanger or next generation sequencing as previously described. 
8,9 Patients were further classified according to (1) the UKALL SCNA classifier into 
good, intermediate or poor risk groups; 13 and (2) IKZF1plus (IKZF1 deletions with 
concomitant CDKN2A/B, PAX5 or PAR1 deletions) as previously described 10 with the 
exception of ERG deletions which were assumed to be absent or, at least, very rare 
in this relapse cohort, given their association with good outcomes in acute 
lymphoblastic leukaemia. 14,15 
 
Outcomes 
As per the original study design, 7  survival analysis considered two end points: 
primary, progression-free (PFS) and secondary, overall survival (OS). PFS was 
calculated from the time from relapse, using the date of registration in ALLR3 until 
induction failure, second relapse, second tumour or death, censoring at last contact if 
no events had been observed. OS was defined as the time from first relapse to death, 
censoring at last contact.  Secondary endpoints included PFS and OS within risk 
groups, by treatment performed (i.e. chemotherapy or SCT) and the proportion of 
patients with MRD levels at TP1 and TP2. Treatment related serious adverse events 
were reported along with the results of the randomisation 7 and not analysed in the 
long-term follow up.  
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Statistical Analysis 
Long-term follow up analysis was planned once the trial closed, though follow-up time 
period was not specified. The primary end point of the previously reported randomised 
analyses was PFS of the randomised cohort.  The primary end point of the long term 
follow-up, post closure of the randomisation, was the survival of the MRD stratified 
patients restricted to BCP-ALL patients with LBMR.  Survival analysis was performed 
using the Kaplan-Meier method and differences in PFS and OS were evaluated using 
the 2-tailed log-rank test. Cumulative incidence of relapse (CIR) was estimated taking 
into account death as a competing risk and then compared using the Gray test. Other 
comparisons were performed using χ2, Fisher’s exact or Mann–Whitney U test as 
appropriate. Univariate and multivariate analyses were performed using Cox 
regression models. The prognostic effect of chemotherapy and SCT was analysed by 
both intention-to-treat and treatment received, and compared using the  Mantel-Byar 
method 15. The majority of prognostic factors had some missing data (supplemental 
table S2, webappendix page 2-6). For multivariate analysis, missing values were 
imputed using multiple imputation by chained equations.13 Sixty imputed datasets 
were created using simulated values for missing values from a set of imputation 
models constructed from all of the potential prognostic factors and outcome variables 
(Nelson-Aalen estimator for each of PFS and OS). Distributions of imputed values 
were visually checked for comparability with the observed data. Cox regression 
analysis was performed on each imputed dataset and the imputation-specific 
coefficients combined using Rubin’s rules.14 The significance of each prognostic factor 
was assessed using the Wald test statistic. Only prognostic factors associated with 
outcome (p<0.1) in univariate analyses were considered in multivariate modelling. The 
final model was built using PFS and backwards selection was performed on the pooled 
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coefficients using p <0.1 to remove variables. The final model was assessed for 
proportional hazards using Schoenfeld residuals 16, evaluated by the Harrell’s c-index 
measure of discrimination and applied to OS data. The c-index was estimated in each 
imputed dataset and then pooled across imputations using Rubin’s rules.  Sensitivity 
analyses were performed using only cases with complete data on the risk factors in 
the final model.   All analyses were performed using Intercooled Stata (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX, USA), and R version 
3.4.3 (http://www.R-project.org). 
 
Role of Funding Source and Sponsor 
Funders and sponsors had no role in the study design, data collection, analyses, 
writing of the report or in the decision to submit the paper for publication. VS, CP, SK, 
AM and LH had access to all the raw data. The corresponding author had full access 
to all of the data and the final responsibility to submit for publication.  
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Results  
A total of 228 BCP acute lymphoblastic leukaemia LBMR patients were treated on the 
ALLR3 protocol from 2nd February 2003 to 28th October 2013. After a median follow-
up time of 84 (Interquartile range (IQ) 48-109) months, the PFS and OS were 60% 
(95% CI 54-70) and 72% (95% CI 65-78) respectively. There were 3 (1%) induction 
failures, 5 (2%) induction deaths and 220 (97%) achieved CR2. For the mitoxantrone 
and idarubicin treatment arms with 173 and 55 patients respectively, the median age 
was 10.1 (IQ 7.33-12.9) and 9.6 (IQ, 6.9-13.2) years respectively and mean age 10.5 
(SD, 3.6) and 10.1 (SD, 3.7) years respectively. Consistent with the previous 
randomised analyses 7,  5-year PFS was significantly higher with mitoxantrone 
treatment – 66% (95% CI 58-73) versus 46% (95% CI 33-59) with idarubicin (p = 
0·0098) although OS did not differ significantly between both groups 75% (CI 67-81) 
versus 63% (CI 49-74), p = 0·10). As reported previously 9, the proportion of MRDlow 
at TP1 was similar with both drug combinations (43% and 42%, respectively). Among 
these late relapsing patients, neither duration of CR1 nor time since stopping frontline 
treatment were significantly associated with outcome (Supplemental Table S2, 
webappendix page 2-6).  
 
Figure 1 shows the outcomes after CR2. MRD at TP1 was evaluable in 192 (87%) 
patients, 82 (43%) of whom were MRDlow.  Of 28 patients with no available MRD, 11 
relapsed 24 months or more after stopping frontline therapy and were allocated, along 
with the MRDlow patients, to the no SCT arm. The remaining 17 patients, who relapsed 
within 24 months of stopping frontline therapy, together with 110 MRDhigh patients, 
were allocated to the SCT arm. Thus 93 (42%) and 127 (58%) were allocated to no-
SCT and SCT respectively. In the no-SCT group, there were 2 treatment related 
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deaths (TRM) prior to completing phase III of treatment. Of the 91 who completed all 
3 phases of chemotherapy, 15 (16%) actually received a SCT, and 11 are in CR2 (1 
TRM and 3 relapses post SCT). Of the 76 who continued on chemotherapy as 
allocated, there were 2 TRM in maintenance therapy (late TRM), 21 (28%) second 
relapses and 53 (70%) are in CR2.  In the SCT group, there were 3 TRM and 4 second 
relapses prior to SCT. 15 patients were not transplanted and 5 (33%) are in CR2. Of 
the 105 transplanted patients, 22 (21%) relapsed again, 14 (13%) died of transplant 
related complications and 69 (66%) are in CR2.  
 
As stratification to SCT or chemotherapy was guided by TP1 MRD levels and duration 
of CR1 similar in both groups (Supplemental Figure S1, webappendix page 8), we 
separately examined the outcomes of patients in whom MRD TP1 was evaluated. 70 
MRDlow patients allocated to no-SCT completed the first 12 weeks and continued on 
chemotherapy. There were 2 (3%) TRM, 19 (27%) second relapses (5 late in 
maintenance and 14 after completing therapy) and 49 (70%) were in CR2 at final follow 
up. 11 MRDlow patients were transplanted of whom 10 are in CR2.  103 MRDhigh 
patients allocated to SCT, reached the time point for SCT. Of 11 not transplanted, 7 
relapsed again, 1 died and 3 are in CR2.  In the 92 transplanted patients, 13 (14%) 
died of transplant related complications, 21 (23%) experienced a second relapse and 
58 (63%) remain in CR2. Survival outcomes were significantly higher in MRDlow with 
5-year PFS of 72% (95% CI 60-81) versus 56% (95% CI 46-65), (p = 0·00781) and 
OS of 87% (95% CI 77-93), versus 64 (54-73), (p = 0·0013) compared to MRDhigh 
(Table 1 and Figure 2 A-B). Patients intended for no-SCT, had a significantly better 
PFS and OS when compared to those intended for a SCT. Although a difference was 
observed in OS when censored at CR2 (p=0·010), there were no differences in 
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outcomes observed in the two groups when analysed as actually treated (Table 1, 
Supplemental Table S3, webappendix page 6).  
 
As TP1 MRD levels were used to allocate patients to SCT we examined the effect of 
SCT versus chemotherapy stratified by TP1 MRD (supplemental table S3, 
webappendix page 6). For patients MRDhigh at TP1 receiving a SCT significantly 
reduced their relapse risk (HR 0.37, 95% CI 0.16-0.83, competing risk analysis Gray’s 
test p = 0.016) compared to chemotherapy alone. In contrast, for patients MRDlow at 
TP1, there was no clear benefit for SCT and all patients had an OS >85% at 5 years 
(Table 2). 
 
We investigated the impact of MRD level at TP2, (before SCT) because high MRD 
levels prior to SCT have been associated with higher relapse rates 16-19. The actual 
TP2 MRD levels and outcome after SCT are shown in supplemental tables S4-S5 
(webappendix pages 6-7). No TP1 MRDlow patients had high MRD levels at TP2 and 
one patient with no MRD result at TP1 was found to have high levels at TP2. The PFS 
and OS of patients transplanted, with a TP2 MRD of <10-4 were 68% (95% CI 53-79) 
and 77% (62-87) respectively while for those with MRD ≥10-4 were 58% (95% CI 36-
75) and 61% (38-77) respectively.  The differences in outcomes were not significant, 
(HR 1.69, 95% CI 0.80-3.61, p = 0.18 for PFS; HR 1.83, 95% CI 0.78-4.27, p = 0.16 
for OS) (Supplemental table S6, webappendix page 7) possibly reflecting the small 
numbers and the unexpected poor outcome of patients with a MRD of 0. Though the 
trial recommended only MD SCT, other donors were used and outcomes within the 
different donor groups were comparable. In the 6 patients where donor source is 
unknown, 5 had events and 1 has a follow up of 2-years (Supplementary Table S2, 
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webappendix page 2-6). Competing risk analyses show relapse as the most frequent 
event post SCT, though transplant related mortality also influenced outcomes 
(Supplemental Figure S2, webappendix page 9). 
 
Patients with standard risk cytogenetics, ETV6-RUNX1 and high hyperdiploid (HeH) 
accounted for 60% patients within this cohort and were associated with improved PFS 
and OS rates (Table 1, Supplementary Table S2, Supplemental Figure S3, 
webappendix page 10). The distribution of patients by cytogenetic risk group was not 
significantly different when stratified by MRD risk group (Table 3). Within the standard 
risk cytogenetic group, there were no differences in the outcome of ETV6-RUNX1 and 
HeH patients: PFS 63% (48-75) v 68% (55-77) and OS 77% (63-87) v 77% (65-85), 
respectively. Although patients with high risk cytogenetics were rare, their outcome 
was poor and similar to patients with early marrow relapses as previously reported 8. 
57-79% of patients were screened at relapse for a range of SCNA and mutations 
affecting 15 genes. The frequency of some of these deletions and mutations varied 
with the underlying cytogenetic risk group and also the likelihood of EOI MRD positivity 
(Figure 3). In particular, deletions affecting IKZF1 were more prevalent in the 
intermediate and high-risk cytogenetic groups, compared with the standard risk group. 
Similarly, these patients were more likely to be MRD positive at EOI (Table 3). IKZF1, 
NR3C1, and PAX5 regulate glucose metabolism in BCP lymphoblasts and 
haploinsufficiency leads to increased glucose metabolism and promotes resistance to 
glucocorticoids 17 establishing a plausible biological mechanism for residual disease 
after therapy. Patients with deletions affecting all 3 genes displayed a trend towards 
inferior outcome and/or likelihood of EOI MRD positivity (Table 1 and Table 3) and 
when grouped collectively achieved statistical significance. Although mutations in 
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NRAS were relatively rare (11% patients), patients with a NRAS mutation had 
significantly inferior PFS and OS (Table 1) despite not being strongly associated with 
EOI MRD. Collectively, patients with a deletion/mutation of 
IKZF1/PAX5/NR3C1/NRAS had a PFS of 50% which was 10% lower than 60% for the 
whole cohort (Table 1). 
 
In order to determine whether or not these risk factors were independent of each other, 
we performed multivariate Cox regression modelling. SCNA and mutations were 
considered individually as well as collectively (IKZF1/PAX5/NR3C1 and 
IKZF1/PAX5/NR3C1/NRAS). Only EOI MRD and NRAS mutations remained 
significant independent risk factors for both PFS and OS, but cytogenetic risk was 
borderline (Table 4). The prognostic performance of both final models was 68% and 
70% respectively as measured by Harrell’s c-index. Adverse genetic features (data 
not shown) did not occur and other risk factors were not associated with post SCT 
relapse (Table S2, webappendix 2-6).  
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Discussion 
The long-term follow-up analyses of ALLR3 demonstrate favourable outcomes in 
BCP-ALL LBMR patients risk stratified at EOI to not receiving a SCT.  There are a 
number of caveats to this observation. The median follow-up time of this cohort is 
around 8-years and while almost all events have occurred within this time, a few late 
relapses are still expected. MRD was not available in 28 (13%) of 220 patients at TP1, 
and they were stratified for SCT based on duration of first remission.  The data 
suggests that time to relapse is not predictive for EOI MRD and patients in this 
category may not have been risk stratified appropriately. Thirty (14%) of the 211 
patients who completed the first 3 blocks of therapy were not treated according to the 
risk stratification. Both our experience and that of the ALL REZ BFM 2002 clinical trial 
3 show that in the real-world about 15% of patients are not able to follow the 
recommended MRD stratified treatment plan. We speculate that for those in the 
MRDlow group, the decision to transplant may reflect intolerance to therapy coupled 
with the availability of a matched donor.  The combined ALLR3 and ALL REZ BFM 
2002 experience suggests that while this is a reasonable approach for such patients,  
fractionated total body irradiation are associated with  long-term toxicities . In the 
MRDhigh patients, it is possible that some patients were not transplanted due to the 
unavailability of a MD as recommended by both studies.  For transplanted patients, 
pre-SCT MRD <10-4 were associated with the best outcomes, though unexpectedly 
the survival post SCT in those with higher TP2 MRD levels were also better than 
previously reported.  19  The numbers are small in this group and factors such as 
conditioning, immunosuppression and graft versus host disease which contribute to 
post SCT outcomes were not analysed. 
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In the patients where EOI MRD was evaluated, MRD <10-4 was associated with 
significantly better outcomes when compared to those with higher levels. Combined 
and isolated LBMR had comparable survival and we conclude that prophylactic cranial 
irradiation is not necessary in isolated LBMR. In the ALL REZ BFM 2002 study, 
outcomes of MRD <10-3 with no-SCT (OS 68%) and MRD ≥10-3 with SCT (OS 73%) 
groups were comparable.3 Though induction therapies were different in REZ2002 and 
ALLR3, by the time patients reach this stage of disease, they have been exposed to 
multiple modalities of therapy both during frontline and relapse treatment. In patients 
allocated for chemotherapy only in this study based on EOI MRD, second relapses 
occurred in 28%. These were mostly after stopping therapy or late in maintenance and 
were often rescued with a SCT in CR3. This implies that these recurrent clones 
continue to be chemosensitive.  Thus, an EOI MRD level of <10-4 appears to be more 
sensitive in identifying LBMR patients who do not require an SCT. It is possible that 
newer more sensitive MRD assays 20 may more clearly predict patients within the 
MRDlow group who will remain in CR2 and not experience a second relapse, but this 
needs prospective evaluation. Those with a TP1 MRD ≥10-4 benefited from SCT. This 
suggests that MRD of ≥10-4 identifies a group with high risk disease. Similar to 
observations of the ALLREZ BFM 2002 study, matched donor SCT appeared to have 
better outcomes, although in both studies the choice of donor did not reach statistical 
significance.  Second relapse rates were high in MRDhigh patients not transplanted. 
With recent advances in transplantation, outcomes for LBMR relapses with a MMD 
SCT are comparable to those with a MD. 21  This suggests that in LBMR MRDhigh 
relapses, SCT with any donor should be the current preferred option. 
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Latency of recurrence (duration of CR1) was not predictive for MRD and differences 
in MRD kinetics are thought to reflect the different underlying biology of acute 
lymphoblastic leukaemia subtypes, and not exclusively drug sensitivity.22  In the 
MRDhigh group, 4 relapses occurred prior to reaching SCT, 1 had high risk cytogenetics 
and the other was IKZF1plus, supporting the contention that MRD reflects the biology 
of the disease. TP53 deletions/mutations did not influence outcomes in this cohort 8,9 
but it should be noted that only one patient harboured a point mutation and the other 
11 TP53 alterations were heterozygous deletions. Univariate analyses showed a 
deleterious effect of IKZF1/PAX5/NR3C1 on outcome and these SCNA were more 
frequent in MRDhigh patients. In murine models, targeting the metabolic processes 
regulated by these genes restored sensitivity to glucocorticoids, offering potential 
targeted therapeutic alternatives in the future.23 The results of this study show that 
SCT offers reasonable outcomes for MRDhigh patients and patients who relapsed post 
SCT did not have these SCNA’s. Both recurrence and transplant mortality contributed 
to the inferior outcomes in transplanted patients and no predictive variables were 
identified for post-SCT relapses in this study. Currently, immune therapies targeting 
expression of antigens on the surface of BCP acute lymphoblastic leukaemia, which 
reduce the MRD burden prior to transplant 24-28 may decrease post SCT recurrences 
in patients MRDhigh at EOI and in future provide alternatives to SCT. The frequency of 
NRAS mutations was 11% overall but 19% among HeH patients. Consistent with the 
previous analysis of the entire ALLR3 cohort,8 NRAS mutations were associated with 
an inferior outcome in patients with LBMR. RAS pathway mutations confer sensitivity 
to MEK inhibition 29 and a phase 1/2 trial is currently assessing selumetinib in 
combination with dexamethasone in treating multiply relapsed childhood acute 
lymphoblastic leukaemia with RAS mutations.30 
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Overall, the results of the ALLR3 clinical trial show that BCP-ALL LBMR with EOI MRD 
of <10-4 have satisfactory outcomes with available therapeutic modalities. For those 
who have a higher MRD at EOI and persistent MRD prior to SCT may benefit from 
enrolment into trials exploring experimental therapies.  
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Legends for Figures 
 
Figure 1. Schematic showing outcome of LBMR BCP-ALL relapses in ALLR3 as per 
allocated treatment. TRM = Treatment related mortality; Thick horizontal bar 
represents completion of all 3 phases of chemotherapy prior to time for SCT. *NA = 
MRD not available. CR1 here refers to time from completing frontline therapy.  
 
Figure 2. 5-year Kaplan-Meier estimates of (A) progression free and (B) overall 
survival in MRDhigh and MRDlow patients (95% CI).  
 
Figure 3. Frequency of somatic copy number alterations and mutations according to  
(A) cytogenetic risk groups and (B).
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Table 1. Frequency and outcome of ALLR3 patients with LBMR, stratified by clinical, treatment, responses and genetic 
features. 
 
  Log  rank analysis    Univariate Cox Regression Analysis 
 Patients (%) PFS (95% CI) p OS (95% CI) p  PFS, HR (95% CI) OS, HR (95% CI) 
Total 228 (100) 60 (54-70)  72 (65-78)     
Age    
 
    
1-9 years 118 (52) 61 (51-70) 0.72 72 (63-80) 0.72  1 1 
10-14 years 77 (34) 62 (50-72)   72 (60-81) 
  0.95 (0.59-1.52), 
0.84 
1.02 (0.58-1.78), 
0.95 
≥14 years 33 (14) 55 (36-71)   70 (50-83) 
  1.22 (0.69-2.15), 
0.50 
1.31 (0.67-2.54), 
0.43 
Sex         
Female 102 (45) 68 (58-77) 0.063 75 (65-83) 0.36  1 1 
Male 126 (55) 55 (45-63) 
 69 (60-77)   1.50 (0.97-2.30), 0.065 
1.27 (0.77-2.09), 
0.36 
Site         
Isolated BM 186 (82) 62 (54-69) 0.6 75 (67-81) 0.24  1 1 
Combined BM* 42 (18) 54 (37-68) 
 60 (43-74)   1.15 (0.69-1.93), 0.60 
1.41 (0.79-2.51), 
0.25 
MRD TP1**         
<10-4 82 (43) 72 (60-81) 0.0078 87 (77-93) 0.0013  1 1 
≥10-4 110 (57) 56 (46-65) 
 64 (54-73)   1.94 (1.18-3.18), 0.009 
2.77 (1.45-5.31), 
0.002 
Intended Treatment1#         
Chemotherapy 93 (42) 68 (57-77) 0.078 84 (74-90) 0.02  1 1 
SCT 127 (58) 59 (49-67) 
 66 (56-74)   1.50 (0.95-2.36), 0.080 
1.94 (1.10-3.41), 
0.022 
Intended and Received 
Treatment2##         
Parker et al_LBMR_Tables 
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Chemotherapy 76 (42) 70 (57-79) 0.39 86 (75-92) 0.046  1 1 
SCT 105 (58) 67 (56-75) 
 71 (60-79)   1.26 (0.74-2.12), 0.39 
1.96 (1.00-3.84), 
0.050 
Actual Treatment###         
Chemotherapy 91 (43) 64 (53-73) 0.96 83 (73-90) 0.11  1 1 
SCT 120 (57) 67 (57-75) 
 72 (63-80)   1.01 (0.64-1.59), 0.96 
1.43 (0.82-2.48), 
0.21 
Genetic Abnormalities         
Cytogenetic Risk $         
Standard 132 (60) 66 (57-74) 0.0006 77 (68-84) 0.0005 
 0.64 (0.41-1.01), 
0.054 
0.61 (0.35-1.04), 
0.070 
Intermediate  69 (32) 56 (43-67)  69 (56-78)   1 1 
High 18 (8) 30 (11-52) 
 39 (16-62)   2.09 (1.08-4.06), 0.030 
2.35 (1.12-4.94), 
0.024 
Individual CNA/Mutations $$         
IKZF1 37 (24) 54 (37-68) 0.13 65 (47-78) 0.058 
 1.51 (0.88-2.59), 
0.14 
1.81 (0.97-3.39), 
0.062 
NR3C1 9 (7) 42 (11-71) 0.4 63 (24-87) 0.96 
 1.48 (0.59-3.72), 
0.41 
1.03 (0.32-3.35), 
0.96 
PAX5 27 (17) 65 (43-80) 0.77 77 (57-89) 0.96 
 0.90 (0.46-1.78), 
0.77 
1.02 (0.47-2.19), 
0.96 
IKZF1/PAX5/NR3C1 56 (34) 49 (35-61) 0.012 63 (49-75) 0.014 
 1.85 (1.34-3.00), 
0.013 
2.01 (1.14-3.57), 
0.016 
NRAS 16 (11) 38 (15-60) 0.03 52 (24-74) 0.12 
 2.10 (1.06-4.15), 
0.034 
1.88 (0.83-4.25), 
0.13 
IKZF1/PAX5/NR3C1/NRAS 63 (38) 50 (37-62) 0.01 65 (52-76) 0.032 
 1.87 (1.15-3.02), 
0.011 
1.85 (1.04-3.28), 
0.035 
 
PFS and OS are shown as 5-year estimates with 95% confidence intervals (CI); Abbreviations:  BM = bone marrow; SCT = stem cell transplant; 
CNA = copy number alteration 
* extramedullary sites CNS (25); Testes (16); Skin (1); ** Measured for those in CR2; # censored at CR2; ## censored at time for SCT analysed as 
intent to treat; ### censored at time for SCT analysed as treated; $ patients with unknown cytogenetics excluded. High risk group includes 
Parker et al_LBMR_Tables 
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iAMP21 (n=11); KMT2A (n=4); TCF3-PBX1 (n=1), Low hypodiplipoid (n=1); Haploid (n=1); $$  data shown is the presence of each CNA or 
mutation and the comparison is for present versus not present. Full details are in the supplemental information (webappendix page 2-6). 
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Table  2. Cumulative incidence functions for competing events in patients receiving chemotherapy or SCT within the 
MRDhigh and MRDlow risk groups 
 
Actual 
Patients 
(%) 
Log  rank analysis 
  
Gray’s 
test 
Univariate Cox Regression Analysis 
(Mantel-Byar method)  
Competing risk 
regression 
    PFS (95% CI) p 
OS (95% 
CI) p CIR  p PFS, HR (95% CI) OS SHR 
MRDhigh                     
Chemo 11 (11) 31 (11-56) 0.1 54 (28-75) 0.37 50 (16-77) 0.03 1 1 1 
SCT 92 (89) 54 (34-71)   59 (36-75)   22 (14-31)  0.57 (0.28-1.19), 0.13 0.69 (0.31-1.56), 0.38 
0.36 (0.16-0.83), 
0.016 
             
    
MRDlow           
Chemo 70 (86) 70 (57-79) 0.2 85 (74-92) 0.74 26 (16-38) 0.23 1 1 1 
SCT 11 (14) 88 (39-98)   100   13 (5-44)   0.29 (0.04-2.15), 0.23 0.71 (0.09-5.56), 0.74 
0.32 (0.04-2.36), 
0.27 
 
 
To compare the prognostic effect of chemotherapy with SCT, the Mantel-Byar method was applied in which time starts at the 
moment of treatment initiation, and all patients begin in the “non-transplant” arm. Those who receive transplant enter the 
“transplant arm” at the time of transplant and remain there until death, second relapse or censoring. 
 
 
 
 
 
 
 
 
 
 
 
Parker et al_LBMR_Tables 
Page 5 of 8 
 
Table 3. Distribution of ALLR3 patients by MRD measured at the end of induction stratified by 
clinical, treatment and genetic features 
 
 MRD
low MRDhigh p* 
N 82 110  
Age     
Mean (SD) 10.33 (3.16) 10.29 (3.60)  
Median (IQR) 10.08 (6.58-12.17) 9.33 (7.25-13.08) 0.68 
Sex    
Female 38 (46) 48 (44) 0.71 
Male 44 (54) 62 (56)  
Drug    
Mitoxantrone 63 (77) 84 (76) 0.94 
Idarubicin  19 (23) 26 (24)  
Site    
isolated BM 66 (80) 91 (83) 0.59 
BM with CNS 7 (9) 12 (11)  
BM with testes or skin 9 (11) 7 (6)  
    
isolated BM 66 (80) 91 (83) 0.69 
Combined BM 16 (20) 19 (17)  
    
Cytogenetic risk    
Standard 56 (71) 59 (57) 0.12 
Intermediate 20 (25) 36 (35)  
High  3 (4) 9 (9)  
Parker et al_LBMR_Tables 
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UKALL CNA profile     
GR 25 (48) 30 (39) 0.33 
IR/PR 27 (52) 46 (61)  
Deletions/Mutations    
IKZF1 9 (17) 21 (28) 0.18 
NR3C1 1 (3) 6 (8) 0.18 
PAX5 7 (13) 17 (22) 0.21 
IKZF1/PAX5/NR3C1 13 (24) 33 (41) 0.039 
CDKN2A/B 18 (35) 25 (33) 0.91 
ETV6 11 (21) 11 (14) 0.33 
TP53 5 (8) 6 (7) 0.74 
P2RY8-CRLF2 4 (8) 6 (8) 1 
NRAS 5 (9) 7 (10) 0.92 
KRAS 7 (13) 7 (10) 0.58 
IKZF1/PAX5/NR3C1/NRAS 16 (29) 36 (44) 0.06 
 
NB Patients without MRD measured at timepoint 1 have been excluded 
* p value for x2, Fisher’s exact or Mann–Whitney U test.   
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Table 4 Final multivariate Cox regression models for progression free and overall survival for ALLR3 patients* with late 
marrow relapses. 
 
Imputation model, N = 220      
      
Progression free Survival         
Variable Comparison 
Hazard 
Ratio 
95% Confidence 
Interval P P (joint test) 
Sex Male vs Female 1.60 1.00-2.56 0.049 - 
Drug 
Idarubicin vs 
Mitoxantrone 1.54 0.96-2.47 0.072 - 
MRD** MRDhigh vs MRDlow 1.71 1.05-2.78 0.031 - 
Cytogenetic risk Standard vs Intermediate 0.74 0.46-1.20 0.22 0.091 
  High vs intermediate 1.68 0.76-3.73 0.20   
NRAS Mutated vs wildtype 2.08 1.06-4.13 0.036 - 
Model performance  C-index = 0.68        
      
Overall Survival           
Sex Male vs Female 1.54 0.88-2.70 0.14   
Drug 
Idarubicin vs 
Mitoxantrone 1.36 0.77-2.40 0.29   
MRD** MRDhigh vs MRDlow 2.42 1.29-4.56 0.006   
Cytogenetic risk Standard vs Intermediate 0.77 0.43-1.38 0.38 0.08 
  High vs intermediate 2.04 0.83-5.02 0.12   
NRAS Mutated vs wildtype 2.27 1.03-5.02 0.040   
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Model performance  C-index = 0.70        
      
      
Available cases, N = 118      
      
Progression free Survival         
Sex Male vs Female 1.68 0.90-3.13 0.10 - 
Drug 
Idarubicin vs 
Mitoxantrone 1.34 0.72-2.48 0.359 - 
MRD** MRDhigh vs MRDlow 2.00 1.05-3.79 0.034 - 
Cytogenetic risk Standard vs Intermediate 0.91 0.49-1.71 0.77 0.63 
  High vs intermediate 1.55 0.51-4.75 0.44   
NRAS Mutated vs wildtype 1.27 0.53-3.07 0.59 - 
Model performance  C-index = 0.64     
          
Overall Survival           
Sex Male vs Female 1.87 0.86-4.08 0.11   
Drug 
Idarubicin vs 
Mitoxantrone 1.15 0.54-2.49 0.72   
MRD** MRDhigh vs MRDlow 2.45 1.08-5.56 0.03   
Cytogenetic risk Standard vs Intermediate 1.03 0.48-2.24 0.94 0.70 
  High vs intermediate 1.75 0.46-6.67 0.41   
NRAS Mutated vs wildtype 1.70 0.63-4.57 0.30   
Model performance  C-index = 0.65     
* Patients who failed induction (n=8) were excluded from the modelling as end of induction MRD was included in imputed missing 
data   
** MRD (minimal residual disease) was measured at the end of induction. High was ≥1x10-4 and Low <1x10-4 
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Supplemental Table S1: Schematic of the ALLR3 Protocol     
ALL R3 
All Patients    No Allo-SCT Patients 
 Induction (weeks 1-4)    Interim Maintenance (weeks 14-21 and 22-29) 
 Dose Days   Dose Days 
Intrathecal Methotrexate#  1, 8  Intrathecal Methotrexate##  1, 36,  
Dexamethasone  PO 20 mg/m2 1-5; 15-19  Vincristine IV 1.5 mg/m2 3, 38 
Mitoxantrone IV* 10 mg/m2 1, 2  Dexamethasone  PO 6 mg/m2 1-5 
OR    HD Methotrexate PO 25 mg/m2 (Q6h, 4 doses ) 22 
Idarubicin IV 10 mg/m2 1, 2  Calcium Folinate PO 10 mg/m2 (2 doses) 24 
Vincristine IV 1.5 mg/m2 3, 10, 17, 24  Mercaptopurine PO 75 mg/m2 1-42 
PEG-Asparaginase IM§ 1000 u/m2 3, 18  Methotrexate PO 20 mg/m2 10, 17, 31, 38 
    Thioguanine PO 40 mg/m2 43-49 
 Consolidation (weeks 5-8)    Cyclophosphamide IV 440 mg/m2 15-19 
Dexamethasone PO 6 mg/m2 1-5  Etoposide IV 150 mg/m2 43-47 
Vincristine IV 1.5 mg/m2 3  Cytarabine IV/sc 50 mg/m2 44-47, 51-53 
Intrathecal Methotrexate  8     
Methotrexate IV 1000 mg/m2 8  Maintenance (88 Weeks) 
PEG-Asparaginase IM 1000 u/m2 9     
Cyclophosphamide IV 440 mg/m2 15-19   Dose Days 
Etoposide IV 100 mg/m2 15-19  Intrathecal Methotrexate##  15 
    Vincristine IV 1.5 mg/m2 1, 29, 57 
Intensification (weeks 9-12)    Dexamethasone  PO 6 mg/m2 1-5, 29-33, 57-61 
Intrathecal Methotrexate  1,22  Mercaptopurine PO 75 mg/m2 1-84 
Dexamethasone PO 6 mg/m2 1-5  Methotrexate PO 20 mg/m2 10, 17, 24, 31, 38, 45,52, 59, 66, 73, 80 
Vincristine IV 1.5 mg/m2 3  Repeated every 12 weeks for 88 weeks   
Cytarabine IV, q12H 3000 mg/m2 1, 2, 8, 9     
Erwinase IM 20000 u/m2 2, 4, 9, 11, 23  
# Not in those who have had cranial 
XRT   
Methotrexate IV 1000 mg/m2 22     
       
Time Point for Allo-SCT and Cranial/Testicular XRT 
 
Detailed protocol is available at 
https://doi.org/10.1371/journal.pone.0108107.s003       
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Supplemental Table S2: Frequency and outcome of ALLR3 patients with late marrow relapses by clinical, treatment and genetic features 
           
 Whole group 
(%) 
Idarubicin Mitoxantrone 
Log Rank Analysis  Univariate Cox Regression Analysis 
PFS (95% 
CI) p  OS (95% CI) p^ 
 PFS, HR (95% CI) OS, HR (95% CI) 
             
Total 228 (100) 55 173 60 (54-70)  72 (65-78)       
             
Age             
1-9 years 118 (52) 32 86 61 (51-70) 
0.72 
72 (63-80) 
0.72 
 1 1 
10-14 years 77 (34) 16 61 62 (50-72) 72 (60-81)  0.95 (0.59-1.52), 0.84 1.02 (0.58-1.78), 0.95 
≥14 years 33 (14) 7 26 55 (36-71) 70 (50-83)  1.22 (0.69-2.15), 0.50 1.31 (0.67-2.54), 0.43 
             
Sex           
Female 102 (45) 24 78 68 (58-77) 0.063 75 (65-83) 0.36 
 1 1 
Male 126 (55) 31 95 55 (45-63) 69 (60-77)  1.50 (0.97-2.30), 0.065 1.27 (0.77-2.09), 0.36 
               
Site           
isolated BM 186 (82) 39 147 62 (54-69) 0.6 75 (67-81) 0.24 
 1 1 
Combined BM* 42 (18) 16 26 54 (37-68) 60 (43-74)  1.15 (0.69-1.93), 0.60 1.41 (0.79-2.51), 0.25 
             
Duration of CR1 (months) - - - -     0.995 (0.99-1.00), 0.34 0.99 (0.98-1.01), 0.34 
Duration from stop to rel (months) - - - -     0.992 (0.98-1.00), 0.10 0.99 (0.98-1.00), 0.13 
           
MRD TP1**           
<10-4 82 (43) 19 63 72 (60-81) 0.0078 87 (77-93) 0.0013 
 1 1 
≥10-4 110 (57) 26 84 56 (46-65) 64 (54-73)  1.94 (1.18-3.18), 0.009 2.77 (1.45-5.31), 0.002 
Not Available 36 10 26 49 (32-64)  62 (43-76)     
           
Intended Treatment1#           
Chemotherapy 93 (42) 19 72 68 (57-77) 0.078 84 (74-90) 0.02 
 1 1 
SCT 127 (58) 32 97 59 (49-67) 66 (56-74)  1.50 (0.95-2.36), 0.080 1.94 (1.10-3.41), 0.022 
           
Intended and Received Treatment##           
Chemotherapy 76 (42) 18 58 70 (57-79) 0.39 86 (75-92) 0.046 
 1 1 
SCT 105 (58) 23 82 67 (56-75) 71 (60-79)  1.26 (0.74-2.12), 0.39 1.96 (1.00-3.84), 0.05 
           
Actual Treatment###           
Chemotherapy 91 (43) 21 70 64 (53-73) 0.96 83 (73-90) 0.11 
 1 1 
SCT 120 (57) 26 94 67 (57-75) 72 (63-80)  1.01 (0.64-1.59), 0.96 1.43 (0.82-2.48), 0.21 
           
MRD at TP2 who received SCT            
MRD <10-3 at TP2  76 (82) 14 62 63 (51-74) 0.86 68 (55-78) 0.97 
 1 1 
MRD ≥10-3 at TP2  17 (17) 5 12 61 (33-80) 73 (43-89)  1.08 (0.47-2.47), 0.86 0.98 (0.37-2.60), 0.97 
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Not Available  27 7 20 81 (59-92)  85 (65-94)     
            
SCT Donor            
Matched Donor§ 84 (74) 19 65 72 (61-81) 
0.6 
79 (67-87) 
0.16 
 0.57 (0.28-1.14), 0.11 0.50 (0.23-1.09), 0.082 
Mismatched Unrelated Donor 14 (12) 4 10 55 (26-77) 55 (26-77)  
1 1 Mismatched Related Donor 3 (3) 1 2 100 100  
Cord 13 (11) 2 11 62 (31-82) 69 (37-87)  
Unknown 6 0 6 NA^^  NA     
           
Number of events           
Progression 90 (39) 31 59        
Relapse  58 (26) 17 41        
Death 64 (28) 21 43        
           
Genetic Analyses           
Cytogenetic Risk           
Standard 132 (60) 31 101 66 (57-74) 
0.0006 
77 (68-84) 
0.0005 
 0.64 (0.41-1.01), 0.054 0.61 (0.35-1.04), 0.07 
Intermediate  69 (32) 18 51 56 (43-67) 69 (56-78)  1 1 
High$ 18 (8) 5 13 30 (11-52) 39 (16-62)  2.09 (1.08-4.06), 0.03 2.35 (1.12-4.94), 0.024 
Missing 9 1 8 89 (43-98)  88 (39-98)     
           
HeH 75 (34) 18 57 68 (55-77)  77 (65-85)   0.60 (0.36-1.02), 0.06 0.60 (0.32-1.12), 0.11 
ETV6-RUNX1 57 (26) 13 44 63 (48-75)  77 (63-87)   0.70 (0.40-1.22), 0.21 0.61 (0.31-1.22), 0.16 
           
UKALL CNA profile           
Good risk 70 (45) 19 51 68 (56-78) 
0.11 
77 (64-85) 
0.27 
 0.70 (0.40-1.23), 0.21 0.63 (0.32-1.22), 0.17 
Intermediate risk 65 (41) 14 51 59 (46-70) 68 (55-78)  1 1 
Poor risk 22 (14) 7 15 53 (31-72) 73 (49-87)   1.43 (0.74-2.78), 0.29 1.13 (0.50-2.56), 0.76 
Missing 71 15 56 55 (42-67)  71 (57-80)     
           
Good risk 70 (45) 19 51 68 (56-78) 0.078 77 (64-85) 0.12 
 1 1 
Intermediate/poor risk 87 (55) 21 66 58 (47-68) 69 (58-78)  1.59 (0.94-2.67), 0.081 1.64 (0.88-3.06), 0.12 
            
Individual CNA           
IKZF1           
Wild type 120 (76) 28 92 65 (56-73) 0.13 75 (65-82) 0.058 
 1 1 
Deleted 37 (24) 12 25 54 (37-68) 65 (47-78)  1.51 (0.88-2.59), 0.14 1.81 (0.97-3.39), 0.062 
NA 71 15 56 55 (42-67)  71 (57-80)     
           
NR3C1           
Wild type 122 (93) 38 84 64 (54-72) 0.4 73 (64-80) 0.96 
 1 1 
Deleted 9 (7) 2 7 42 (11-71) 63 (24-87)  1.48 (0.59-3.72), 0.41 1.03 (0.32-3.35), 0.96 
NA 97 15 82 58 (47-68)  73 (62-81)     
           
PAX5           
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Wild type 130 (83) 30 100 62 (53-70) 0.77 71 (62-79) 0.96 
 1 1 
Deleted 27 (17) 10 17 65 (43-80) 77 (57-89)  0.90 (0.46-1.78), 0.77 1.02 (0.47-2.19) ,0.96 
NA 71 15 56 55 (42-67)  71 (57-80)     
            
IKZF1/PAX5/NR3C1           
Wild type 109 (99) 27 82 69 (59-77) 0.012 78 (68-85) 0.014 
 1 1 
Deleted  56 (34) 16 40 49 (35-61) 63 (49-75)  1.85 (1.14-3.00), 0.013 2.01 (1.14-3.57), 0.016 
NA 63 12 51 56 (41-69)  70 (55-80)     
           
IKZF1 plus           
No 138 (87) 32 106 62 (53-70) 0.98 71 (63-79) 0.88 
 1 1 
Yes 20 (13) 8 12 65 (40-82) 75 (50-89)  0.99 (0.47-2.08), 0.98 1.07 (0.45-2.52), 0.89 
NA 70 15 55 56 (42-68)  72 (58-81)     
           
CDKN2A/B           
Wild type 100 (64) 26 74 62 (52-71) 0.75 75 (64-82) 0.26 
 1 1 
Deleted 57 (36) 14 43 63 (48-74) 69 (55-79)  1.09 (0.65-1.82), 0.75 1.41 (0.78-2.56), 0.26 
NA 71.00 15 56 55 (42-67)  71 (57-80)     
           
BTG1           
Wild type 150 (96) 40 100 63 (54-70) 0.59 73 (65-80) 0.23 
 1 1 
Deleted 7 (4) 0 7 57 (17-84) 54 (13-83)  1.37 (0.43-4.39), 0.59 2.02 (0.62-6.56), 0.24 
NA 71 15 56 55 (42-67)  71 (57-80)     
           
ETV6           
Wild type 129 (82) 34 95 64 (54-72) 0.54 73 (64-81) 0.59 
 1 1 
Deleted 28 (18) 6 22 57 (36-73) 67 (47-82)  1.22 (0.65-2.28), 0.55 1.22 (0.59-2.54), 0.59 
NA 71.00 15 56 55 (42-67)  71 (57-80)     
           
EBF1           
Wild type 150 (96) 38 112 64 (56-71) 0.032 73 (65-80) 0.34 
 1 1 
Deleted 7 (4) 2 5 29 (4-61) 57 (17-84)  2.63 (1.05-6.59), 0.04 1.76 (0.54-5.69), 0.35 
NA 71 15 56 55 (42-67)  71 (57-80)     
           
RB1           
Wild type 146 (93) 37 109 62 (54-70) 0.76 71 (63-78) 0.17 
 1 1 
Deleted 11 (7) 3 8 64 (30-85) 91 (51-99)  1.15 (0.46-2.88), 0.76 0.28 (0.04-2.01), 0.21 
NA 71 15 56 55 (42-67)  71 (57-80)     
           
TP53           
Wild type 169 (93) 44 125 59 (51-67) 0.73 72 (64-78) 0.54 
 1 1 
Deleted$$ 12 (7) 7 5 50 (21-74) 58 (27-80)  1.16 (0.50-2.66), 0.73 1.33 (0.53-3.34), 0.54 
NA 47 4 43 69 (51-81)  76 (59-87)     
           
PAR1           
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Wild type 145 (93) 36 109 63 (54-70) 0.36 74 (65-80) 0.075 
 1 1 
Deleted 11 (7) 2 8 55 (23-78) 51 (18-77)  1.53 (0.61-3.81), 0.37 2.28 (0.90-5.82), 0.083 
NA 72 16 56 56 (42-68)  71 (57-80)     
           
Mutations           
NRAS           
Wild type 134 (89) 35 99 66 (57-73) 0.03 76 (68-83) 0.12 
 1 1 
Mutated 16 (11) 4 12 38 (15-60) 52 (24-74)  2.10 (1.06-4.15), 0.034 1.88 (0.83-4.25), 0.13 
NA 78 16 62 56 (43-67)  68 (55-78)     
           
KRAS           
Wild type 132 (88) 33 99 62 (53-70) 0.76 74 (65-81) 0.8 
 1 1 
Mutated 18 (12) 6 12 67 (40-83) 72 (46-87)  0.88 (0.38-2.05), 0.77 1.13 (0.44-2.88), 0.80 
NA 78 16 62 56 (43-67)  68 (55-78)     
           
PTPN11           
Wild type 135 (90) 37 98 61 (52-69) 0.33 73 (65-80) 0.55 
 1 1 
Mutated 15 (10) 2 13 80 (50-93) 79 (49-93)  0.60 (0.22-1.67), 0.33 0.70 (0.22-2.28), 0.56 
NA 78 16 62 56 (43-67)  68 (55-78)     
           
FLT3           
Wild type 144 (96) 37 107 62 (53-69) 0.28 73 (65-80) 0.54 
 1 1 
Mutated 6 (4) 2 4 83 (27-97) 83 (27-97)  0.35 (0.05-2.55), 0.30 0.54 (0.07-3.97), 0.55 
NA 78 16 62 56 (43-67)  68 (55-78)     
           
CBL1           
Wild type 149 (99) 39 110 63 (55-70) 0 74 (66-81) 0 
 1 1 
Mutated 1 (1) - 1 - -  NA NA 
NA 78 16 62 56 (43-67)  68 (55-78)     
           
IKZF1/PAX5/NR3C1/NRAS           
Wild type 103 (62) 25 78 70 (60-78) 0.01 77 (68-85) 0.032 
 1 1 
Deleted  63 (38) 18 45 50 (37-62) 65 (52-76)  1.87 (1.15-3.02), 0.011 1.85 (1.04-3.28), 0.035 
NA 62 12 50 56 (40-68)   69 (54-80)         
PFS and OS are shown as 5-year estimates with 95% confidence intervals (CI); BM = bone marrow; HeH = High Hyperdiploid     
Ida = Idarubicin; Mito = Mitoxantrone; SCT = stem cell transplant; CNA = somatic copy number alteration       
For genetic analyses, % are shown for data available and not available data is not included in total or in log rank analyses     
* extramedullary sites CNS (25); Testes (16); Skin (1)         
** Measured for those in CR2, § Matched Donor = matched sibling, matched related and matched unrelated; # censored at CR2; ## censored at time for SCT and treated as intended  
$ includes iAMP21 (11); KMT2A (4); TCF3-PBX1 (1), Low hypodiplipoid (1); Haploid (1); $$ Deleted and mutated in one patient    
^Missing data group not considered in this test          
^^5 patients have events within 2 years and the sixth patient had follow-up 2 years;  
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Supplemental Table S3: Outcomes after SCT and Chemotherapy at different TP1 MRD levels 
  
  SCT Chemotherapy 
MRD TP1 Total (%) N  2nd relapse  TRM N (%) 2nd relapse  TRM 
0 35 (18) 5 (5) 0 0 29 (36) 9 6 
> 0 & < 10-4 32 (17) 5 (5) 2 2 27 (33) 6 2 
≥10-4 & < 10-3 33 (17) 25 (24) 2 6 6 (6) 3 3 
≥10-3   57 (30) 51 (50) 14 16 1 (1) 0 0 
Negative, Unknown level 19 (10) 2 (2) 0 0 17 (21) 6 3 
Positive, Unknown level 17 (9) 15 (14) 4 4 2 (2) 1 0 
Unknown 35 17 3 4 10 4 3 
 
 
Supplemental Table S4: Correlation of TP1MRDhigh with TP2 MRD 
 
TP2 MRD  Number positive at TP1 
TP1 MRD positive with 
SCT 
0 10 (18) 9 (17) 
> 0 & < 10-4 22 (39) 21 (40) 
≥10-4 & <10-3 13 (23) 12 (23) 
≥10-3   11 (20) 10 (19) 
Unknown 56 52 
 
 
Supplemental Table S5: TP2 MRD and Outcomes  
 
 All patients with TP2 MRD (N = 119) TP2 MRD patients with SCT (N = 93) 
TP2 MRD  Total PFS  OS Total PFS  OS 
0 15 (12) 58 (29-79) 73 (43-89) 9 (10) 53 (18-80) 53 (18-80) 
> 0 & < 10-4 40 (34) 73 (56-85) 78 (58-89) 26 (28) 76 (50-90) 76 (50-90) 
≥10-4 & < 10-3 13 (11) 46 (19-70) 51 (21-74) 12 (13) 56 (2-74) 56 (24-79) 
≥10-3 17 (14) 56 (29-76) 68 (38-85) 16 (17) 59 (31-79) 72 (41-89) 
Negative 34 (29) 58 (39-74) 70 (50-84) 30 (32) 63 (41-79) 70 (48-84) 
Unknown 109 60 (50-69) 73 (63-80) 27 81 (59-92) 85 (65-94) 
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Supplemental Table S6: TP2 MRD Outcomes at 10-4 
 
TP2 MRD 
(all patients) 
Total 
(%) PFS  OS  
    5-year rate HR (95% CI), p 5-year rate HR (95% CI), p 
< 10-4 55 (70) 68 (53-79) 1 77 (62-87) 1 
≥ 10-4 24 (30) 58 (36-75) 1.69 (0.80-3.61), 0.18 61 (38-77) 
1.83 (0.78-4.27), 
0.16 
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Figure S1. Duration of CR1 in patients with MRDlow  and MRDhigh 
 
 MRDlow MRDhigh 
Number of Patients 82.0 110.0 
   
Minimum 31.0 31.0 
25% Percentile 41.8 44.0 
Median 53.0 52.0 
75% Percentile 68.5 70.0 
Maximum 152.0 155.0 
   
Mean 58.0 58.9 
Std. Deviation 23.2 22.9 
Std. Error of Mean 2.6 2.2 
   
Lower 95% CI of mean 52.9 54.6 
Upper 95% CI of mean 63.1 63.3 
 
 
 
 
 
    Green line = mean; Red lines = 95% Confidence Intervals 
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Figure S2. Cumulative probability of events in MRDhigh patients post SCT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.
00
0.
25
0.
50
0.
75
1.
00
Cu
m
ula
tiv
e 
pr
ob
ab
ilit
y o
f e
ve
nt
0 2 4 6 8
Follow−up time (years)
Relapse
TRM
Parker et al Supplemental 
Page 10 of 11 
 
 
Figure S3. 5-year Kaplan-Meier estimates of (A) progression free and (B) overall survival in cytogenetic risk groups 
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ALL R3 Study Group 
 
Country    Study Group     Coordinator  Number of Patients 
 
United Kingdom and Ireland  Childrens Cancer and Leukaemia Group   Vaskar Saha   166 
 
Australia and New Zealand Australia and New Zealand Childrens  Tamas Révész    39 
    Haematology and Oncology Group 
 
The Netherlands   Dutch Childrens Oncology Group   Peter Hoogerbrugge   23 
